Impact of the COVID-19 pandemic onthe multidisciplinary management of breast cancer: Initialanalysis of the american society of breast surgeonsmastery COVID-19 registry
Authors: L. G. Wilke, T. T. Nguyen, Q. Yang, B. M. Hanlon, K. A. Wagner, P. Strickland, E. A. Brown, J. Dietz, J. C. Boughey
Journal: Cancer Research (2021)

Background: The COVID-19 pandemic rapidly altered health care worldwide  To save protective equipment andminimize exposures, many hospitals stopped some or all cancer surgery, leading oncologic providers to quicklyadjust patient management  The goal of this study is to describe the breast cancer patient level changes whichoccurred during the initial months of COVID-19 in the United States  Methods: The American Society of BreastSurgeons developed a COVID-19 specific registry, within the established HIPPA compliant Mastery of BreastSurgery Program  Surgeons entered patient demographic data as well as their surgical and medical care(Neoadjuvant endocrine (NET) vs Neoadjuvant chemotherapy (NCT))  Data fields tracked whether decisions were usual for that practice, or modified due to COVID-19  Results: Between 3/1 and 6/17/2020, data from 1781 patients was entered by 154 surgeons  Mean age was 63, 78% Caucasian, 10% African American, 6% Hispanic;withgeographic distribution ranging from 10 8% Northwest to 29 5% Northeast  Initial consultation took place in-personfor 94 8% and only 5 2% (89) occurred via video/telephone  To date, just over 1% (14) of patients tested positive forCOVID-19  Mean invasive tumor size was 21 2mm and 15 7% were node positive  Of 1445 invasive breast cancers75% (1081) were ER +/HER2-, 13 5% (195) HER2+, 11 1% (160) triple negative (TNBC) (9/missing data)  DCIScomprised 18 2% (325) of the cohort  Of 267 cases of ER+ DCIS, 49% (131) had primary surgery and 49% (130)  received NET  The majority of NET use was due to COVID-19, 95% (124)  Almost all (50/52) ER- DCIS underwentprimary surgery (6/missing ER)  Table 1 describes the management for the 1436 patients with invasive cancer withknown biomarkers  NET due to COVID-19 was utilized in 45% (482), with only 5% (54) as part of usual practice Increasing age was not a statistically significant factor in the use of NET (OR 0 99, 95% CI 0 97-1 01)  Incomparison to patients from the Northwest, patients from the Southwest and Northeast had the greatest use of NET(COVID-19) vs NET(usual) (ORs 14 4 and 4 6) Genomic assay testing was performed on the core biopsy in 216patients, with 65% (141) due to COVID-19  Among the patients who had genomic testing due to COVID-19, 116(82%) had NET, 18 (13%) had NCT, with the remaining having primary surgery  Of 472 patients treated with primarysurgery for which the impact of COVID-19 was provided, surgery was delayed in 20% (96)  Patients from theNortheast had a 2 1 x greater odds of having surgery delayed in comparison to those from the Midwest  Patientsalso experienced changes to their surgical plan with the most common changes being 6% (27) converting frommastectomy to breast conservation and 7% (34) from mastectomy with reconstruction to mastectomy withoutreconstruction  Conclusion: COVID-19 led to significant modifications in breast cancer treatment, including highrates of NET, genomic assay testing on core biopsies as well as delays in surgery;each of which were consistent with the prioritization and treatment recommendations from the COVID-19 Pandemic Breast Cancer Consortium The majority of patients with TNBC and HER2+ disease received guideline concordant NCT  The ASBrS MasteryCOVID-19 registry provides a snapshot into the rapid care changes caused by the pandemic, has ongoing dataentry and analysis and will enable understanding of the impact on long term breast cancer outcomes